CNIPA Issues Notification Of Patent Grant For bioAffinity Technologies' Composition And Method For Selectively Killing Cancer By Targeting CD320 And LRP2 Receptors On Cell Membrane

Company research targets topical application for treatment of skin cancers

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane.

The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the Company's new U.S. Patent No. 12,305,171.

The invention uses small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro research demonstrates this siRNA-driven double knockdown effectively targets cancer cells from multiple tumor types, including lung, breast, prostate, brain, and skin, without harming normal cells, suggesting a universal mechanism of action.

bioAffinity is exploring the application of this technology as a topical treatment specifically designed for cutaneous malignancies and neoplasms of the skin. This development aligns closely with the Company's broader strategy of addressing cancer through both early-stage diagnostics, exemplified by CyPath® Lung, and innovative therapeutic approaches.

bioAffinity continues to advance its high-growth core diagnostic platform, CyPath® Lung, an accurate, noninvasive test for early-stage lung cancer detection, while simultaneously leveraging its scientific expertise toward novel therapeutic solutions that address critical unmet medical needs in oncology.